
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our leadership team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine
The SOPHiA GENETICS team is thrilled to see you at our Fireside chat on Monday, May 4th from 15.30 to 16.15, in Room Delhi – Level 0.
“Liquid Biopsy at a Tipping Point in Precision Oncology”
Join Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS, Elena Guerini Rocco, MD, Director of the Oncology Genetics Unit, IEO – Istituto Europeo di Oncologia, and Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca for an insightful conversation about the liquid biopsy movement.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.